5 Key Takeaways

• 1

  The PRISM trial evaluates 4D-150, an intravitreal gene therapy for wet AMD, delivering aflibercept and an inhibitory RNA for VEGF-C.

• 2

  Results show 57% of patients were injection-free at 52 weeks, increasing to 80% for those diagnosed within 6 months.

• 3

  Efficacy data indicates stable visual acuity and optical coherence tomography findings for up to 104 weeks.

• 4

  Safety results are promising, with only 2.8% of patients experiencing transient side effects and 99% completing steroid taper.

• 5

  Ongoing phase 3 trials, 4FRONT-1 and 4FRONT-2, will further assess the efficacy and durability of 4D-150 compared to standard treatments.